Results 11 to 20 of about 10,879 (228)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon   +21 more
doaj   +1 more source

The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection

Hepatology, 2017
Sanjay Bansal, Chuan-Hao Lin, Jessica Wen   +2 more
exaly   +2 more sources

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study [PDF]

Clinical and Molecular Hepatology, 2021
Background/Aims Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. Methods Between 2015 to 2019,
Oidov Baatarkhuu, Jae Seung Lee, Jazag Amarsanaa, Do Young Kim, Sang Hoon Ahn, Nyamsuren Naranzul, Damba Enkhtuya, Nagir Choijamts, Purev Batbayar, Radnaa Otgonbayar, Bat-Ulzii Saruul, Chuluunbaatar Gantuul, Baljinnyam Gegeebadrakh, Narangerel Tuvshinbayar, Dorjgotov Badamsuren, Galsan Ulzmaa, Jamiyandorj Otgonbold, Kwang-Hyub Han   +17 more
doaj   +1 more source

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
ABSTRACT Direct‐acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype‐specific to pan‐genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines.
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +2 more sources

Ledipasvir/Sofosbuvir [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker, Ross Jason, Bindler   +2 more
openaire   +2 more sources

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection

IDCases, 2023
Persistent Hepatitis E Virus infection (HEV) is a rare but increasingly recognised condition in immunocompromised individuals. Untreated, this infection can rapidly progress to cirrhosis.
J. Gallacher, Yusri Taha Y, A. da Silva Filipe, S. Ijaz, S. McPherson   +4 more
semanticscholar   +1 more source

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C

Digestive Diseases and Sciences, 2023
Background and Aims Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether ledipasvir/sofosbuvir is effective for treating both PCT and CHC, we treated patients with CHC + PCT solely with ledipasvir/sofosbuvir and
H. Bonkovsky, Sean Rudnick, Christopher D. Ma, J. Overbey, Kelly Wang, Denise Faust, C. Hallberg, Karli Hedstrom, H. Naik, A. Moghe, K. Anderson   +10 more
semanticscholar   +1 more source

Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report

Case Reports in Dermatology, 2021
Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with ...
Meghan L. McPhie, Kevin Y.M. Ren, J. Michael Hendry, Sonja Molin, Thomas Herzinger   +4 more
doaj   +1 more source

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

One Health & Risk Management, 2020
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU, Liliana HODOROGEA, Tiberiu HOLBAN   +2 more
doaj   +3 more sources

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?

International Journal of Infectious Diseases, 2021
Objectives: The aim of this study was to evaluate the efficacy and safety of sofosbuvir/ledipasvir ± ribavirin in Malagasy patients with hepatitis C virus genotypes 1 and 2, in real conditions.
Chantelli Iamblaudiot Razafindrazoto, Anjaramalala Sitraka Rasolonjatovo, Tovo Harimanana Rabenjanahary, Nitah Harivony Randriamifidy, Andry Lalaina Rinà Rakotozafindrabe, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy   +6 more
doaj   +1 more source